NCT06089863

Brief Summary

Cerebellar ataxia is a pathology linked to the lesion of the cerebellum or the afferent and/or efferent cerebellar pathways. The aetiology can be an acquired cerebral lesion, following a chemical poisoning or a genetic degenerative lesion (for example : Friedreich's ataxia, spinocerebellar ataxias, etc.). As reported by the latest estimate available, genetic degenerative cerebellar ataxias affect approximately 6,000 patients in France (Orpha.net). Symptoms suffered by ataxic patients are : problems and gait disorders along with difficulties in coordination resulting in ataxia, uncoordinated movements. These symptoms cause a decrease in the quality of life on patients with spinocerebellar ataxia. The symptoms improvement linked to the cerebellar syndrome is based on rehabilitation that can be supplemented by use of technical aids. Current scientific knowledge confirms that intensive rehabilitation by physiotherapy and occupational therapy in patients with degenerative ataxias improves cerebellar symptoms. Nevertheless, the choice rehabilitation technique stay at the appreciation of the therapist. From the observation, the investigators have designed an intensive multidisciplinary rehabilitation program, called PAMPERO, with partner patients member of two genetic degenerative ataxia patient organisations. This 5-weeks program has been used in clinic during 3 years on 28 patients. It appears to be the only one in France. The preliminary results show a positive effect on ataxia symptom. Nevertheless, the duration of the benefice over time and the effect on the quality of life stay unknown. However, the quality of life is mainly affected by the participation restriction due to the risk of falling. The most frequent complaint from partner patient is the diminution of the social interaction resulting of the incapacity to move without risk. The present protocol aimed at evaluating the Rehabilitation Program in collaboration with partner patient on the symptom intensity, activity and quality of life on genetic and degenerative ataxia. This PAMPERO program's effect will be assessed by comparing the difference of Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA) at inclusion and 3 months after the end of rehabilitation.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
17mo left

Started Feb 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Feb 2024Oct 2027

First Submitted

Initial submission to the registry

October 9, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 18, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2027

Last Updated

January 17, 2024

Status Verified

October 1, 2023

Enrollment Period

3.4 years

First QC Date

October 9, 2023

Last Update Submit

January 15, 2024

Conditions

Keywords

Genetic ataxiaDegenerative ataxiaRehabilitationCerebellar ataxia

Outcome Measures

Primary Outcomes (1)

  • Scale for the Assessment and Rating of Ataxia (SARA)

    Intensity of symptom measured by to Scale for the Assessment and Rating of Ataxia (SARA). Scores are from 0 to 42. An higher score is associated with a worse outcome.

    Inclusion ; 3 months after the end of rehabilitation

Secondary Outcomes (14)

  • Scale for the Assessment and Rating of Ataxia (SARA)

    Inclusion ; Immediately or 1 week after the end of rehabilitation ; 6 months after the end of rehabilitation

  • Score of the Mini-BESTest scale

    Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

  • Eyes open postural surface

    5 weeks

  • Displacement length of the center of mass as a function of time eyes open

    5 weeks

  • Scale of Short Falls Efficacy Scale International (Short FES-I)

    Inclusion ; Immediately or 1 week after the end of rehabilitation ; 3 months after the end of rehabilitation ; 6 months after the end of rehabilitation

  • +9 more secondary outcomes

Study Arms (2)

PAMPERO program group

EXPERIMENTAL

This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity.

Other: PAMPERO program

Usual Care intervention group

NO INTERVENTION

Usual Rehabilitation of the patient after the inclusion. 0 to 2 physical therapy sessions and 0 to 2 Speech therapy sessions each week usually constitute this program. This rehabilitation highly depends on the patients usual preferences. Some patients have no rehabilitation in the daily care while some have more.

Interventions

This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow : * 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object * 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority * 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick * 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture * 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation

PAMPERO program group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years
  • Patients with genetic and degenerative cerebellar ataxia
  • Diagnostic of cerebellar ataxia confirmed by anatomic MRI
  • Affiliated to a social insurgence regime or similar
  • Patients who have given their free, informed and express consent
  • Walking patients (who can walk unsupervised on flat ground with the help of proper technique : categories greater than 4 on the New Functional Ambulation Classification scale)
  • Patients who have already benefited from a hospitalization of more than 3 weeks for rehabilitation during the last 12 months
  • Patients participating simultaneously in another research whose objective would be the evaluation of a therapy, medicinal or not, likely to improve neurological or functional recovery
  • Pregnants, parturient or breastfeeding
  • Patients deprived of their liberty by a judicial or administrative decision
  • Psychiatric care patients
  • Patients admitted to Patients admitted to a health or social establishment for purposes other than research for purposes other than research
  • Major patients protected by the Law

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Service de Rééducation Fonctionnelle (S.S.R.) Val Rosay

Saint-Didier-au-Mont-d'Or, 69370, France

Location

Service de Médecine Physique et Réadaptation (M.P.R) de l'Hôpital Bellevue

Saint-Etienne, 42100, France

Location

Service de Rééducation Fonctionnelle (S.S.R.) de l'Hôpital Henry Gabrielle Hospices Civils de Lyon

Saint-Genis-Laval, 69230, France

Location

MeSH Terms

Conditions

AtaxiaGenetic Diseases, InbornCerebellar Ataxia

Condition Hierarchy (Ancestors)

DyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCerebellar DiseasesBrain DiseasesCentral Nervous System Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 9, 2023

First Posted

October 18, 2023

Study Start

February 1, 2024

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

October 1, 2027

Last Updated

January 17, 2024

Record last verified: 2023-10

Locations